Advertisement
Singapore markets close in 2 hours 43 minutes
  • Straits Times Index

    3,292.86
    +0.17 (+0.01%)
     
  • Nikkei

    38,222.40
    -51.65 (-0.13%)
     
  • Hang Seng

    18,189.11
    +426.08 (+2.40%)
     
  • FTSE 100

    8,121.24
    -22.89 (-0.28%)
     
  • Bitcoin USD

    57,536.98
    -2,334.41 (-3.90%)
     
  • CMC Crypto 200

    1,259.70
    -11.04 (-0.87%)
     
  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     
  • Dow

    37,903.29
    +87.37 (+0.23%)
     
  • Nasdaq

    15,605.48
    -52.34 (-0.33%)
     
  • Gold

    2,322.60
    +11.60 (+0.50%)
     
  • Crude Oil

    79.53
    +0.53 (+0.67%)
     
  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     
  • FTSE Bursa Malaysia

    1,576.32
    +0.35 (+0.02%)
     
  • Jakarta Composite Index

    7,116.59
    -117.61 (-1.63%)
     
  • PSE Index

    6,653.77
    -46.72 (-0.70%)
     

Lonza names Siegfried Holding boss as new CEO

Logo of Swiss contract drug maker Lonza is seen in Basel

ZURICH (Reuters) -Swiss contract drug manufacturer Lonza on Tuesday named Wolfgang Wienand, CEO of Siegfried Holding, as its new chief executive.

Wienand, who has led the Swiss contract development and manufacturing (CDMO) company since 2019, will replace Chairman Albert Baehny, who has served as interim CEO at Lonza since October 2023.

Wienand will join Basel-based Lonza in the summer of 2024, the company said, while Baehny will retire following a transition period.

Before becoming CEO at Siegfried, Wienand was chief scientific officer and chief strategy officer at the company, which produces pharmaceutical ingredients and finished products.

ADVERTISEMENT

"The board is delighted to have appointed a seasoned CEO with a strong and established track record of success in the CDMO industry," Baehny said in a statement.

"Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise," he added.

(Reporting by John Revill, Editing by Rachel More)